TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY One-Year Results
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES37(3) · pp.561 · 2017
- 피인용
- Web of Science 14
- JCR IF
- JCR 2016 3.7
- ISSN
- 0275-004X
저자
초록
Purpose: To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose $ 3 best-corrected visual acuity (BCVA) lines. The number of intravitreal injections and recurrences as well as the maximum treatment interval without recurrence were analyzed. Results: The mean BCVA improved from 0.64 +/- 0.42 logMAR (median, 20/80) at baseline to 0.30 +/- 0.31 logMAR (median, 20/30) at 12 months (P < 0.001). The mean central subfield macular thickness improved from 307.0 +/- 70.2 mu m to 237.5 +/- 64.4 mu m (P < 0.001). None of the subjects lost $ 3 lines, and 15 (51.7%) gained >= 3 lines. The mean number of injections was 7.0. The mean maximum treatment interval without recurrence was 10.0 weeks. After the loading phase, 12 eyes (41.4%) showed no recurrence. Seven eyes (24.1%) demonstrated disease activity at 12 months, and 4 (13.8%) of them were never dry during the entire 12-month follow-up duration. Conclusion: The TER effectively improved visual acuity in PCV while reducing the number of injections.
키워드
polypoidal choroidal vasculopathytreat-and-extendVERTEPORFIN PHOTODYNAMIC THERAPYMACULAR DEGENERATION
식별자
- WoS UID
- 000397987600030



로그인
연구물 목록으로